2019
DOI: 10.1126/sciadv.aav6322
|View full text |Cite
|
Sign up to set email alerts
|

Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4 + T cell activation and HIV-1 latency reversal

Abstract: A proposed strategy to cure HIV uses latency-reversing agents (LRAs) to reactivate latent proviruses for purging HIV reservoirs. A variety of LRAs have been identified, but none has yet proven effective in reducing the reservoir size in vivo. Nanocarriers could address some major challenges by improving drug solubility and safety, providing sustained drug release, and simultaneously delivering multiple drugs to target tissues and cells. Here, we formulated hybrid nanocarriers that incorporate physicochemically… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
36
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(36 citation statements)
references
References 40 publications
0
36
0
Order By: Relevance
“…The developed DOX-loaded Mag-Alg-PEG-FA co-MIONS were characterized by their physicochemical characteristics (size and ζ-potential), colloidal stability, and ability to load and release the drug. The release of the drug was studied at different pH values (blood pH 7.4 and an acidic pH 6.0, representing the acidic tumor environment) and in different biological media [Roswell Park Memorial Institute (RPMI) 1640 medium 14 and blood plasma 15 ], as well as under hyperthermia in a specific magnetic fluid hyperthermia (MFH) device. Optimal nanoparticle compositions were studied for their anticancer activity and their intracellular localization in human cancer cell lines expressing and not expressing (for comparison) the FRα receptor.…”
Section: Introductionmentioning
confidence: 99%
“…The developed DOX-loaded Mag-Alg-PEG-FA co-MIONS were characterized by their physicochemical characteristics (size and ζ-potential), colloidal stability, and ability to load and release the drug. The release of the drug was studied at different pH values (blood pH 7.4 and an acidic pH 6.0, representing the acidic tumor environment) and in different biological media [Roswell Park Memorial Institute (RPMI) 1640 medium 14 and blood plasma 15 ], as well as under hyperthermia in a specific magnetic fluid hyperthermia (MFH) device. Optimal nanoparticle compositions were studied for their anticancer activity and their intracellular localization in human cancer cell lines expressing and not expressing (for comparison) the FRα receptor.…”
Section: Introductionmentioning
confidence: 99%
“…Through chemical bioconjugation, lipid-coated PLGA nanomaterials first target T helper cells, which express the CD4 + (cluster of differentiation 4) protein on their surface. [ 47 ] Subsequent nanomaterials were designed to release encapsulated latency-reversing agents (LRAs) sustainably, ensuring synergistic effects against human immunodeficiency virus type 1 (HIV-1). In addition, nanoparticles were engineered to offer the controlled release of anti-HIV drugs when triggered by external energy.…”
Section: Nanotechnology Versus the Virusmentioning
confidence: 99%
“…Another common example is the combination of polymers and liposomes. Based on this strategy, Cao et al recently developed a hybrid nanocarrier that encapsulates hydrophobic HIV drugs into PLGA polymeric cores, which is then inserted into lipid bilayers [76]. This hybrid nanocarrier was also conjugated with different antibodies to target CD4 + T cells [76].…”
Section: Hybrid Nanocarriersmentioning
confidence: 99%
“…Based on this strategy, Cao et al recently developed a hybrid nanocarrier that encapsulates hydrophobic HIV drugs into PLGA polymeric cores, which is then inserted into lipid bilayers [76]. This hybrid nanocarrier was also conjugated with different antibodies to target CD4 + T cells [76]. This strategy significantly improved the latency and decreased the toxicity of some HIV drugs [76].…”
Section: Hybrid Nanocarriersmentioning
confidence: 99%
See 1 more Smart Citation